礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LLY 礼来

休市中 10-11 16:00:00 EDT

932.06

+21.37

+2.35%

盘后930.01

-2.05-0.22%

19:59 EDT

最高932.24	最低911.18	成交量229.39万
今开916.04	昨收910.69	日振幅2.31%
总市值8,859亿	流通市值8,836亿	总股本9.50亿
成交额21.21亿	换手率0.24%	流通股本9.48亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"LLY","market":"US","secType":"STK","nameCN":"礼来","latestPrice":932.06,"timestamp":1728676800000,"preClose":910.69,"halted":0,"volume":2293874,"hourTrading":{"tag":"盘后","latestPrice":930.01,"preClose":932.06,"latestTime":"19:59 EDT","volume":131771,"amount":122814033.1738,"timestamp":1728691187438},"delay":0,"floatShares":948000000,"shares":950425778,"eps":8.121151,"marketStatus":"休市中","marketStatusCode":7,"change":21.37,"latestTime":"10-11 16:00:00 EDT","open":916.04,"high":932.24,"low":911.1845,"amount":2120792948.7536,"amplitude":0.02312,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":8.121151,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1728892800000},"adr":0,"listingDate":102488400000,"adjPreClose":910.69,"adrRate":0,"dividendRate":0.005214,"preHourTrading":{"tag":"盘前","latestPrice":914.81,"preClose":910.69,"latestTime":"09:29 EDT","volume":7691,"amount":7045110.5890999995,"timestamp":1728653399999},"postHourTrading":{"tag":"盘后","latestPrice":930.01,"preClose":932.06,"latestTime":"19:59 EDT","volume":131771,"amount":122814033.1738,"timestamp":1728691187438},"volumeRatio":1.0830629113566128,"impliedVol":0.4175,"impliedVolPercentile":0.9365},"requestUrl":"/m/hq/s/LLY","defaultTab":"news","newsList":[{"id":"2474555002","title":"美国肥胖群体的福音：FDA考虑允许复配版礼来(LLY.US)减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=2474555002","media":"智通财经网","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474555002?lang=zh_cn&edition=full","pubTime":"2024-10-12 15:22","pubTimestamp":1728717751,"startTime":"0","endTime":"0","summary":"(FDA)在周五同意重新考虑上个月所作出的决定，即禁止私人的药物配制商销售他们自己复合制作版本的礼来公司减肥以及治疗糖尿病药物。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20241012/20241012152350_55532.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20241012/20241012152350_55532.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1193023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"美国肥胖群体的福音：FDA考虑允许复配版礼来(LLY.US)减肥药","news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IE00BJLML261.HKD","LU0061475181.USD","LU0820561909.HKD","LU1061106388.HKD","IE00B2B36J28.USD","IE0004445239.USD","IE00BFTCPJ56.SGD","LU1093756168.USD","IE00BJT1NW94.SGD","LU0385154629.USD","LU0417517546.SGD","LU0109391861.USD","LU0256863902.USD","LU0708995401.HKD","LU1023059063.AUD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0689472784.USD","BK4588","LU0289739699.SGD","LU0122379950.USD","BK4581","LU0106261372.USD","LU0238689110.USD","IE00B1BXHZ80.USD","LU0006306889.USD","LU0320765059.SGD","LU0097036916.USD","LU0672654240.SGD","BK4534","LU0466842654.USD","BK4516","LU0354030438.USD","LU1069344957.HKD","LU1064131342.USD","BK4533","IE0009355771.USD","LU0256863811.USD","LU1093756325.SGD","LU0114720955.EUR","LU1267930730.SGD","LU1057294990.SGD","LU0058720904.USD","LU0640476718.USD","LU0882574139.USD","LU0820561818.USD","LLY","BK4585","IE00BK4W5M84.HKD","LU0456855351.SGD"],"gpt_icon":1},{"id":"2474102203","title":"24小时环球政经要闻全览 | 10月12日","url":"https://stock-news.laohu8.com/highlight/detail?id=2474102203","media":"格隆汇","labels":["Economic Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474102203?lang=zh_cn&edition=full","pubTime":"2024-10-12 07:58","pubTimestamp":1728691136,"startTime":"0","endTime":"0","summary":"全球热点狙击","market":"us","thumbnail":"https://img3.gelonghui.com/e42b8-9d2f8444-fedd-4251-b687-92a544fcf261.jpg?guru_height=716&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/e42b8-9d2f8444-fedd-4251-b687-92a544fcf261.jpg?guru_height=716&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1149178","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Economic Data","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU0672654240.SGD","LU1629891620.HKD","LU1861220033.SGD","SG9999015952.SGD","LU0289739699.SGD","LU0234570918.USD","IE00BSNM7G36.USD","LU1861215975.USD","LU0006306889.USD","LU0238689110.USD","LU0823411888.USD","BK4187","JPM","BK4564","LU0256863902.USD","BK4533","LU0061475181.USD","LU0820562030.AUD","IE00B1BXHZ80.USD","LU1023059063.AUD","LU0719512351.SGD","LLY","LU0106261372.USD","BK4007","LU1057294990.SGD","IE00BWXC8680.SGD","LU1093756168.USD","UBER","LU0823414478.USD","IE00BJT1NW94.SGD","LU1548497426.USD","BK4534","LU0348723411.USD","BK4511","LU2213496289.HKD","BK4555","LU0053666078.USD","BA","BK4548","LU0316494557.USD","IE00BK4W5M84.HKD","LU0094547139.USD","LU0082616367.USD","TSLA","LU0109391861.USD","LU1720051108.HKD","LU0417517546.SGD","LU1852331112.SGD","IE00BK4W5L77.USD","LU0320765059.SGD","LU0471298777.SGD","LU0234572021.USD"],"gpt_icon":1},{"id":"2474680011","title":"减肥药Zepbound有望明年在日本获批 礼来涨逾1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2474680011","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474680011?lang=zh_cn&edition=full","pubTime":"2024-10-12 00:03","pubTimestamp":1728662613,"startTime":"0","endTime":"0","summary":"周五，礼来(LLY.US)股价震荡上行，截至发稿，上涨1.18%，报921.435美元。消息面上，礼来公司首席执行官周五表示，减肥药Zepbound有望明年在日本获批。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-10-11/doc-incseytr8162787.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["LU0708995401.HKD","IE00BJJMRZ35.SGD","BK4588","IE0002141913.USD","BK4516","IE00BJLML261.HKD","IE00B1BXHZ80.USD","LU0471298777.SGD","IE0009355771.USD","LU0943347566.SGD","LU0823416689.USD","LU0882574139.USD","LU0820561818.USD","IE00B2B36J28.USD","LU0096364046.USD","LU1023059063.AUD","LU1064131342.USD","IE00BFTCPJ56.SGD","LU0471298694.HKD","LU0456855351.SGD","BK4534","LU0320765059.SGD","BK4007","LU0006306889.USD","LU0079474960.USD","IE00BJT1NW94.SGD","LU1093756325.SGD","IE00BK4W5L77.USD","BK4585","LU0122379950.USD","LU0417517546.SGD","LU0672654240.SGD","LU1035775433.USD","LU1267930730.SGD","LU0385154629.USD","LU0114720955.EUR","LU0354030511.USD","LU0198837287.USD","LU0094547139.USD","LU0640476718.USD","LU0109391861.USD","LLY","IE0004445239.USD","LU0106261372.USD","LU0256863811.USD","LU0689472784.USD","LU1069344957.HKD","LU0097036916.USD","IE00B4R5TH58.HKD","BK4533"],"gpt_icon":0},{"id":"2474013589","title":"美股异动 | 减肥药Zepbound有望明年在日本获批 礼来(LLY.US)涨逾1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2474013589","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474013589?lang=zh_cn&edition=full","pubTime":"2024-10-11 22:53","pubTimestamp":1728658422,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，礼来(LLY.US)股价震荡上行，截至发稿，上涨1.18%，报921.435美元。消息面上，礼来公司首席执行官周五表示，减肥药Zepbound有望明年在日本获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1192987.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0106261372.USD","BK4007","LU1069344957.HKD","LU0456855351.SGD","LU0385154629.USD","LU0820561818.USD","IE00BFTCPJ56.SGD","LU0289739699.SGD","LU0122379950.USD","LU0882574055.USD","LU1064131342.USD","LU0256863902.USD","LU0320765059.SGD","IE00BK4W5M84.HKD","LU0708995401.HKD","LU0672654240.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0417517546.SGD","LU0689472784.USD","BK4581","LU1057294990.SGD","LU0114720955.EUR","IE00BJT1NW94.SGD","BK4534","LU0198837287.USD","LU1035775433.USD","LU0640476718.USD","IE0004445239.USD","LLY","LU0256863811.USD","LU0061475181.USD","LU0471298777.SGD","LU0466842654.USD","BK4516","IE00BK4W5L77.USD","LU0820561909.HKD","IE00B4R5TH58.HKD","LU1093756168.USD","IE00BJLML261.HKD","LU1023059063.AUD","LU0471298694.HKD","LU0097036916.USD","IE00B1BXHZ80.USD","LU1093756325.SGD","IE0009355771.USD","LU1267930730.SGD","LU0354030511.USD","GB00BDT5M118.USD","LU1061106388.HKD"],"gpt_icon":0},{"id":"2474097095","title":"据日经新闻：礼来(LLY.N)负责人表示，日本政府有望在未来几个月内批准该公司广受欢迎的肥胖治疗药物Zepbound。","url":"https://stock-news.laohu8.com/highlight/detail?id=2474097095","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474097095?lang=zh_cn&edition=full","pubTime":"2024-10-11 22:21","pubTimestamp":1728656487,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["IE00BJLML261.HKD","LU0061475181.USD","LU1061106388.HKD","IE00B2B36J28.USD","NIYmain","IE00BFTCPJ56.SGD","LU1093756168.USD","IE00BK4W5L77.USD","IE00BJT1NW94.SGD","LU1035775433.USD","LU0417517546.SGD","LU0109391861.USD","LU0079474960.USD","LU0471298694.HKD","LU0943347566.SGD","LU0256863902.USD","GB00BDT5M118.USD","LU0708995401.HKD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0689472784.USD","LU0122379950.USD","LU0106261372.USD","LU0238689110.USD","LU0006306889.USD","LU0320765059.SGD","LU0097036916.USD","JNImain","BK4534","NKmain","BK4516","LU1069344957.HKD","LU0965088593.USD","BK4533","LU0094547139.USD","LU0471298777.SGD","LU1093756325.SGD","LU1267930730.SGD","LU1057294990.SGD","LU0058720904.USD","LU0640476718.USD","LU0882574139.USD","LU0823416689.USD","LU0820561818.USD","LU0096364046.USD","LLY","BK4585","JMImain","LU0354030511.USD","LU0456855351.SGD"],"gpt_icon":0},{"id":"2474609669","title":"礼来将在中国生产减重药，多家巨头争夺中国“胖人”市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2474609669","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474609669?lang=zh_cn&edition=full","pubTime":"2024-10-11 20:51","pubTimestamp":1728651060,"startTime":"0","endTime":"0","summary":"也就是说，未来礼来供应中国市场的减重药不仅可能产自中国，而且还将出口欧洲。此外，礼来还在德国及爱尔兰等国家拥有减重药生产设施。多家巨头争夺中国“胖人”市场礼来将在中国扩大减重药生产规模，也给竞争对手诺和诺德施压。届时两款药物是否会迎来正式的商业化上市值得关注，这将标志着两大巨头正式在中国市场上展开激烈竞逐，争霸数亿规模的“胖人”市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410112052529f3a970a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410112052529f3a970a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1061106388.HKD","LU0006306889.USD","LU0820561909.HKD","LU0061475181.USD","LU0689472784.USD","LU1057294990.SGD","LU0354030438.USD","BK4585","IE0002141913.USD","LU0094547139.USD","IE0004445239.USD","LU0256863811.USD","LU0640476718.USD","LU0882574055.USD","LU0943347566.SGD","LU1093756168.USD","LU0114720955.EUR","IE0009355771.USD","LU0466842654.USD","LU1064131342.USD","IE00B1BXHZ80.USD","LU0820561818.USD","IE00BK4W5M84.HKD","LU0385154629.USD","LU0198837287.USD","LU0079474960.USD","GB00BDT5M118.USD","BK4007","IE00BJJMRZ35.SGD","LU0096364046.USD","LU0058720904.USD","LU0823416689.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","IE00BJLML261.HKD","LU0109391861.USD","LU0882574139.USD","BK4588","LU1023059063.AUD","LU1069344957.HKD","LLY","LU0471298694.HKD","LU1035775433.USD","LU0708995401.HKD","LU0354030511.USD","LU1093756325.SGD","LU0097036916.USD","IE00BJT1NW94.SGD","LU0122379950.USD","BK4534"],"gpt_icon":0},{"id":"2474236065","title":"韦格威生产商诺和诺德在印度大力投资人才和人工智能合作伙伴关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2474236065","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474236065?lang=zh_cn&edition=full","pubTime":"2024-10-11 18:00","pubTimestamp":1728640808,"startTime":"0","endTime":"0","summary":"道伯说，诺和诺德还与印度的10家初创公司建立了合作关系，利用人工智能完成一系列任务，包括总结文件、提取见解和检查编辑错误。押宝印度诺和诺德并不是唯一一家在印度押下重注的大型制药公司。诺和诺德全球安全评估工作的一半由其印度业务部门负责，该部门负责跟踪药物副作用报告并与全球卫生监管机构分享。诺和诺德没有对扩大印度中心或其人工智能合作伙伴关系的投资金额发表评论，但确认它愿意与印度更多的此类初创企业合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GB00BDT5M118.USD","BK4516","LU0079474960.USD","IE0004445239.USD","LU0061475181.USD","LU0868494617.USD","BK4533","LU1261432733.SGD","LU0122379950.USD","LU0237698245.USD","LU0708995401.HKD","LU1989771016.USD","LU0109391861.USD","IE00B1BXHZ80.USD","LU0225771236.USD","LU0256863811.USD","LU0943347566.SGD","LU2242652126.USD","LU0225284248.USD","LU1093756168.USD","LU1035775433.USD","LU0354030511.USD","LU1093756325.SGD","LU1074936037.SGD","LU0006306889.USD","BK4534","LU1585245621.USD","LLY","LU0114720955.EUR","BMY","IE00BJLML261.HKD","IE00BJJMRZ35.SGD","BK4559","LU0985481810.HKD","LU1023059063.AUD","NVO","LU0094547139.USD","BK4007","LU1061106388.HKD","LU0882574055.USD","LU1571399168.USD","LU0058720904.USD","LU0096364046.USD","LU0471298694.HKD","LU1057294990.SGD","IE00BJT1NW94.SGD","LU0321505868.SGD","IE0002141913.USD","LU0289739699.SGD","LU0354030438.USD"],"gpt_icon":0},{"id":"2474058348","title":"礼来投资15亿元扩产苏州工厂，减肥药产能战火烧到国内","url":"https://stock-news.laohu8.com/highlight/detail?id=2474058348","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474058348?lang=zh_cn&edition=full","pubTime":"2024-10-11 14:43","pubTimestamp":1728629012,"startTime":"0","endTime":"0","summary":"实际上，自2020年以来，礼来已宣布投资超200亿美元扩产，包括在美国、爱尔兰、德国等处自建和收购工厂。礼来不断投资扩产的背后，也体现了企业看好糖尿病与减肥药物替尔泊肽的未来前景。两个月后，礼来宣布恢复供应替尔泊肽，但其被列入FDA的短缺药品名单。礼来的替尔泊肽于2023年11月被FDA获批为肥胖治疗药物，其美国商品名为Zepbound。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241011144513959f5953&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241011144513959f5953&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0094547139.USD","LU1267930730.SGD","GB00BDT5M118.USD","LU0471298777.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU1023059063.AUD","IE00B4R5TH58.HKD","LU0456855351.SGD","LU0109391861.USD","LU0882574055.USD","LU0385154629.USD","LU1035775433.USD","LU0466842654.USD","BK4581","BK4007","IE0009355771.USD","LU0354030511.USD","LU0096364046.USD","LU1093756168.USD","LU1061106388.HKD","LU1057294990.SGD","LU0256863811.USD","BK4534","LLY","LU0289739699.SGD","IE00B1BXHZ80.USD","LU0640476718.USD","LU0354030438.USD","LU0198837287.USD","IE00BK4W5M84.HKD","BK4533","LU0320765059.SGD","LU0820561818.USD","LU1093756325.SGD","LU1064131342.USD","LU0823416689.USD","LU0689472784.USD","LU0238689110.USD","IE0002141913.USD","IE00BJLML261.HKD","LU0079474960.USD","LU0471298694.HKD","LU0820561909.HKD","LU0114720955.EUR","BK4588","LU0006306889.USD","IE00BK4W5L77.USD","LU0058720904.USD","BK4516"],"gpt_icon":0},{"id":"2474086702","title":"礼来投资两亿美金扩充中国产能","url":"https://stock-news.laohu8.com/highlight/detail?id=2474086702","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474086702?lang=zh_cn&edition=full","pubTime":"2024-10-11 09:36","pubTimestamp":1728610606,"startTime":"0","endTime":"0","summary":"10月11日，礼来宣布投资两亿美金扩充中国产线。礼来在华唯一的工厂位于苏州。这一投资项目将为其重磅药物做好准备。糖尿病适应证在华获批之后，礼来的明星药物替尔泊肽今年7月在华获批减重适应证。近三十年来，礼来在苏州累计投资了20亿美金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202410113202824371.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202410113202824371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0640476718.USD","LU0882574139.USD","BK4516","LU0106261372.USD","LU0689472784.USD","BK4533","LU0354030511.USD","LU0708995401.HKD","LU0820561818.USD","IE00BJJMRZ35.SGD","LU1023059063.AUD","BK4585","LU0006306889.USD","LU1057294990.SGD","IE00B1BXHZ80.USD","IE0004445239.USD","LU0058720904.USD","LU0823416689.USD","LU1064131342.USD","IE00BK4W5M84.HKD","LU0471298694.HKD","BK4007","IE0009355771.USD","LU1093756325.SGD","LU0385154629.USD","GB00BDT5M118.USD","LU0114720955.EUR","LU0320765059.SGD","LU1267930730.SGD","LU0417517546.SGD","LU0882574055.USD","LLY","IE0002141913.USD","LU0122379950.USD","LU1093756168.USD","BK4588","IE00B4R5TH58.HKD","LU0109391861.USD","LU0198837287.USD","LU0097036916.USD","LU0238689110.USD","IE00BK4W5L77.USD","LU0466842654.USD","LU1035775433.USD","LU0096364046.USD","LU0471298777.SGD","LU0943347566.SGD","LU0354030438.USD","LU0061475181.USD","BK4534"],"gpt_icon":0},{"id":"2474905722","title":"礼来下跌1.21%，报908.65美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2474905722","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474905722?lang=zh_cn&edition=full","pubTime":"2024-10-11 01:22","pubTimestamp":1728580951,"startTime":"0","endTime":"0","summary":"10月11日，礼来(LLY)盘中下跌1.21%，截至01:22，报908.65美元/股，成交6.9亿美元。财务数据显示，截至2024年06月30日，礼来收入总额200.71亿美元，同比增长31.42%；归母净利润52.1亿美元，同比增长67.62%。大事提醒：11月7日，礼来将披露2024财年三季报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际披露日期以公司公告为准）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/10/11012243898482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU0417517546.SGD","BK4585","IE0002141913.USD","LU0256863902.USD","LU0114720955.EUR","LU0079474960.USD","BK4516","LU0354030511.USD","IE00B2B36J28.USD","LU0256863811.USD","LU0198837287.USD","LU1023059063.AUD","LU1093756168.USD","IE00BFTCPJ56.SGD","LU0882574055.USD","LU0289739699.SGD","LU0820561818.USD","LU0672654240.SGD","LU0094547139.USD","LU0471298777.SGD","LU0466842654.USD","LU1061106388.HKD","LU1093756325.SGD","BK4588","LU0456855351.SGD","GB00BDT5M118.USD","LU0106261372.USD","IE00B4R5TH58.HKD","LU0320765059.SGD","LU0882574139.USD","LU0943347566.SGD","LU0689472784.USD","LU0096364046.USD","LU0823416689.USD","LU0097036916.USD","LU0238689110.USD","LU1069344957.HKD","LU1064131342.USD","LU0820561909.HKD","LU0385154629.USD","LU0354030438.USD","LLY","IE00BK4W5M84.HKD","LU0640476718.USD","IE00BK4W5L77.USD","IE0009355771.USD","BK4007","LU1057294990.SGD","LU1267930730.SGD","BK4581"],"gpt_icon":0},{"id":"2474773332","title":"礼来任命首任首席人工智能官 Thomas J. Fuchs","url":"https://stock-news.laohu8.com/highlight/detail?id=2474773332","media":"观点网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474773332?lang=zh_cn&edition=full","pubTime":"2024-10-10 08:41","pubTimestamp":1728520860,"startTime":"0","endTime":"0","summary":"观点网讯：10月10日，全球领先的制药公司礼来宣布，Thomas J. Fuchs将于2024年10月21日起担任公司首任首席人工智能官。Fuchs将负责为礼来公司的人工智能计划提供全面的愿景、战略指导和领导，涉及药物发现、临床试验、生产、商业活动和内部职能。Fuchs在人工智能领域的专业背景和丰富经验，将为礼来公司带来新的视角和创新动力。此前，Fuchs曾担任西奈山人工智能与人类健康学院院长和首任系主任、西奈山哈索-普拉特纳数字健康研究所所长，以及西奈山伊坎医学院人工智能与计算病理学教授。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241010085101959be6b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241010085101959be6b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417517546.SGD","BK4585","IE0002141913.USD","LU0256863902.USD","LU0114720955.EUR","LU0079474960.USD","BK4516","LU0354030511.USD","IE00B2B36J28.USD","BK4533","LU0256863811.USD","LU0198837287.USD","IE00BFTCPJ56.SGD","LU0882574055.USD","LU0289739699.SGD","LU0820561818.USD","LU0672654240.SGD","LU0471298777.SGD","LU1061106388.HKD","LU0466842654.USD","LU1093756325.SGD","BK4588","LU0456855351.SGD","GB00BDT5M118.USD","LU0106261372.USD","IE00B4R5TH58.HKD","LU0320765059.SGD","LU0882574139.USD","LU0943347566.SGD","IE00BJLML261.HKD","LU0096364046.USD","LU0689472784.USD","LU0823416689.USD","LU0097036916.USD","LU0238689110.USD","LU1069344957.HKD","LU1064131342.USD","LU0820561909.HKD","LU0385154629.USD","BK4534","LU0354030438.USD","LLY","IE00BK4W5M84.HKD","LU0640476718.USD","IE00BK4W5L77.USD","IE0009355771.USD","BK4007","LU1267930730.SGD","IE00BJJMRZ35.SGD","BK4581"],"gpt_icon":0},{"id":"2474223035","title":"礼来中国宣布管理团队重大任命","url":"https://stock-news.laohu8.com/highlight/detail?id=2474223035","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474223035?lang=zh_cn&edition=full","pubTime":"2024-10-09 21:02","pubTimestamp":1728478927,"startTime":"0","endTime":"0","summary":"南方财经10月9日电，记者获悉，礼来中国区总裁兼总经理HuzurDevletsah在今日向员工宣布了一项重大的管理层任命，自10月10日起，严琼就任糖尿病产品事业部副总裁，成为礼来中国管理团队一员，直接向HuzurDevletsah汇报。礼来中国相关负责人已向21世纪经济报道记者证实这一消息。据了解，严琼曾在诺华担任肿瘤治疗领域高级副总裁。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202410093200606329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0256863902.USD","LU0006306889.USD","IE00B4R5TH58.HKD","LU0672654240.SGD","LU0061475181.USD","LU0820561909.HKD","BK4516","LU1057294990.SGD","LU0354030438.USD","BK4533","BK4585","IE00BK4W5L77.USD","IE0002141913.USD","LU0094547139.USD","IE0004445239.USD","LU0882574055.USD","LU0943347566.SGD","LU1093756168.USD","IE0009355771.USD","LU1064131342.USD","IE00B1BXHZ80.USD","LU0820561818.USD","IE00BK4W5M84.HKD","LU0385154629.USD","LU0198837287.USD","LU0079474960.USD","BK4007","IE00BJJMRZ35.SGD","LU0096364046.USD","LU0058720904.USD","LU0823416689.USD","LU1267930730.SGD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU0471298777.SGD","IE00BJLML261.HKD","LU0882574139.USD","BK4588","LU1023059063.AUD","BK4581","LU1069344957.HKD","LLY","LU0471298694.HKD","LU0320765059.SGD","LU0354030511.USD","LU1093756325.SGD","LU0097036916.USD","IE00BJT1NW94.SGD","LU0122379950.USD","LU0106261372.USD"],"gpt_icon":0},{"id":"2474040242","title":"BUZZ-WeightWatchers跳涨近40%，原因是揭示了诺和诺德的Wegovy的访问权限","url":"https://stock-news.laohu8.com/highlight/detail?id=2474040242","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474040242?lang=zh_cn&edition=full","pubTime":"2024-10-09 02:54","pubTimestamp":1728413659,"startTime":"0","endTime":"0","summary":"     10月8日 - ** WW国际  ，也被称为WeightWatchers，周二股价大涨38.1%至1.09美元，该公司称将提供诺和诺德  流行肥胖药Wegovy的  复方版本。** 周二迄今已成交约2800万股，为2023年4月以来最繁忙的交易时段** Wegovy和礼来公司  的Zepbound能帮助患者平均减重20%，这两种药物的需求飙升导致了短缺，而根据美国法规，制药商可以生产这两种药物。** 鉴于 Ozempic 和 Wegovy 等品牌药物持续短缺，WeightWatchers 致力于确保我们的会员仍能获得有效的替代品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU0079474960.USD","BK4007","LU0096364046.USD","LU1035775433.USD","LU0466842654.USD","BK4581","LU0256863811.USD","LU1069344957.HKD","BK4588","LU0820561909.HKD","LU1064131342.USD","LU0385154629.USD","IE0004445239.USD","LU0823416689.USD","LU0471298777.SGD","LU0354030438.USD","LU0882574055.USD","IE00BJLML261.HKD","LU0198837287.USD","LU0640476718.USD","LU0456855351.SGD","LU0943347566.SGD","HIMS","NVO","LU0471298694.HKD","LU0689472784.USD","LU0122379950.USD","LU0882574139.USD","LU0354030511.USD","LU1267930730.SGD","BK4192","LU0114720955.EUR","BK4196","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","GB00BDT5M118.USD","LU0820561818.USD","LU0097036916.USD","IE00B2B36J28.USD","LU1061106388.HKD","LU1093756325.SGD","IE0002141913.USD","BK4516","LLY","WW","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BKVL7J92.USD","BK4585"],"gpt_icon":0},{"id":"2473472471","title":"礼来(LLY)涨超1% 仿制药团体起诉FDA 减肥药短缺争议升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2473472471","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473472471?lang=zh_cn&edition=full","pubTime":"2024-10-08 23:24","pubTimestamp":1728401065,"startTime":"0","endTime":"0","summary":"金吾财讯 | 礼来(LLY)涨超1%，截至发稿，报914.67美元。代表生产礼来(LLY)减肥药仿制品的公司的团体——外包设施协会(Outsourcing Facilities Association)——在德克萨斯州联邦法院对美国食品和药物管理局(FDA)提起诉讼，指控FDA将礼来公司的药物从短缺药物名单中剔除的决定是“武断、反复无常且违法”的。原告认为，FDA的决定剥夺了患者获取重要药品的权利，并请求法院撤销或修改FDA的这一决定。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210625/NzNiZjRmZDM5NGRiODIwMzA3NTA2OTY0NQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/NzNiZjRmZDM5NGRiODIwMzA3NTA2OTY0NQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"280694","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0289739699.SGD","LU1069344957.HKD","LU0882574139.USD","LU0708995401.HKD","LLY","IE00BK4W5M84.HKD","BK4516","BK4588","LU1093756325.SGD","LU0006306889.USD","BK4533","LU0256863811.USD","BK4585","IE00B1BXHZ80.USD","LU0114720955.EUR","LU0079474960.USD","LU0385154629.USD","LU0058720904.USD","IE0004445239.USD","GB00BDT5M118.USD","LU0094547139.USD","LU0061475181.USD","LU1057294990.SGD","LU1093756168.USD","LU0689472784.USD","LU1061106388.HKD","LU0471298694.HKD","IE00BK4W5L77.USD","LU0943347566.SGD","IE00BJJMRZ35.SGD","LU0882574055.USD","IE0009355771.USD","IE00BJLML261.HKD","LU0096364046.USD","LU0097036916.USD","LU0354030511.USD","LU1035775433.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0820561818.USD","LU0820561909.HKD","BK4534","LU1023059063.AUD","LU0109391861.USD","LU0466842654.USD","IE00BJT1NW94.SGD","LU0354030438.USD","BK4007","LU0122379950.USD"],"gpt_icon":0},{"id":"2473721644","title":"更新版 2-WeightWatchers 将提供诺和诺德减肥药的复方制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2473721644","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473721644?lang=zh_cn&edition=full","pubTime":"2024-10-08 21:38","pubTimestamp":1728394716,"startTime":"0","endTime":"0","summary":"更新版 2-WeightWatchers 将提供诺和诺德减肥药的复方制剂第3段增加了远程保健公司的背景资料，第5段增加了价格资料。路透10月8日 - WeightWatchersWW.O周二表示，它将提供诺和诺德NOVOb.CO流行的肥胖症药物Wegovy的复方制剂，作为其体重管理计划的一部分。\"首席执行官塔拉-科蒙特在一份声明中说：\"鉴于Ozempic和Wegovy等品牌药物持续短缺，WeightWatchers致力于确保我们的会员仍能获得有效的替代品。诺和诺德的 Wegovy 和 Ozempic 仍在该名单上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241008:nL4T3LK1AC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0471298777.SGD","BK4532","IE0009355771.USD","LU0823416689.USD","LU0882574139.USD","BK4192","LU0820561818.USD","IE00B2B36J28.USD","LU0096364046.USD","LU1023059063.AUD","LU1064131342.USD","IE00BFTCPJ56.SGD","LU0154236417.USD","LU0289739699.SGD","IE00BZ1G4Q59.USD","LU0456855351.SGD","BK4196","BK4534","LU0320765059.SGD","LU0006306889.USD","IE00BK4W5L77.USD","LU1057294990.SGD","IE00BK4W5M84.HKD","IE00BKVL7J92.USD","BK4585","LU0417517546.SGD","LU0238689110.USD","LU0672654240.SGD","LU1267930730.SGD","LU0385154629.USD","LU0114720955.EUR","WW","LU0198837287.USD","LU0094547139.USD","LU0640476718.USD","LLY","HIMS","LU0106261372.USD","LU0256863902.USD","LU1093756168.USD","LU0689472784.USD","LU1069344957.HKD","LU0466842654.USD","LU0097036916.USD","NVO","IE00B4R5TH58.HKD","LU0820561909.HKD","BK4581","BK4533"],"gpt_icon":0},{"id":"2473273514","title":"仿制药团体起诉FDA 声称礼来减肥药的短缺问题并未真正结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2473273514","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473273514?lang=zh_cn&edition=full","pubTime":"2024-10-08 20:58","pubTimestamp":1728392336,"startTime":"0","endTime":"0","summary":"原告认为，礼来减肥药的短缺问题并未真正结束，FDA的决定剥夺了患者获取重要药品的权利，并请求法院撤销或修改FDA的这一决定。据了解，礼来公司的减肥药自2022年以来一直面临短缺问题，导致FDA允许药房仿制并出售这些药物的非品牌版本，通常价格更便宜。然而，FDA最近宣布短缺问题已解决，配制药房不再被广泛允许仿制这些药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100820585995985af0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100820585995985af0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GB00BDT5M118.USD","IE00B4R5TH58.HKD","LU0106261372.USD","LU0320765059.SGD","LU0689472784.USD","IE0004445239.USD","IE00B2B36J28.USD","LU1023059063.AUD","LU0385154629.USD","IE0009355771.USD","BK4581","LLY","LU0058720904.USD","LU0471298694.HKD","LU0096364046.USD","LU1267930730.SGD","LU0354030438.USD","BK4534","LU1061106388.HKD","LU0672654240.SGD","LU0079474960.USD","IE00BJT1NW94.SGD","LU0094547139.USD","IE0002141913.USD","LU0820561818.USD","LU0097036916.USD","LU0471298777.SGD","BK4516","LU0198837287.USD","IE00BFTCPJ56.SGD","LU0114720955.EUR","IE00B1BXHZ80.USD","IE00BJLML261.HKD","LU0417517546.SGD","BK4585","LU0238689110.USD","LU0820561909.HKD","IE00BK4W5L77.USD","LU1035775433.USD","LU0466842654.USD","LU1064131342.USD","BK4533","LU0640476718.USD","LU0122379950.USD","LU0256863811.USD","IE00BK4W5M84.HKD","LU0823416689.USD","LU1069344957.HKD","LU0109391861.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2473905455","title":"礼来能否反超诺和诺德？后来者将居上乎？","url":"https://stock-news.laohu8.com/highlight/detail?id=2473905455","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473905455?lang=zh_cn&edition=full","pubTime":"2024-10-08 07:31","pubTimestamp":1728343895,"startTime":"0","endTime":"0","summary":"01诺和、礼来销售表现大PK诺和诺德与礼来日益胶着的竞争局面，也反映在这两大制药巨头第二季度的财报中。诺和诺德以27%的同比增长率排名第二。与礼来的增长相比，诺和诺德本周下调了全年利润预期。GlobalData预测，最终礼来将在减肥药市场取代诺和诺德成为领导者，到2030年，Zepbound的销售额将达到272亿美元，而Wegovy预计将产生187亿美元的销售额。迫于礼来在价格上的举措，诺和诺德有可能也会对其减肥药Wegovy进行降价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410080744309f3053d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410080744309f3053d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BJLML261.HKD","LU0640476718.USD","IE0002141913.USD","IE00BZ1G4Q59.USD","BK4533","LU0289739699.SGD","LU1061106388.HKD","LLY","LU0006306889.USD","LU0079474960.USD","LU0320765059.SGD","IE00B4R5TH58.HKD","LU0708995401.HKD","LU0943347566.SGD","LU0882574055.USD","LU0097036916.USD","IE00B1BXHZ80.USD","BK4585","LU0198837287.USD","LU0106261372.USD","IE0009355771.USD","GB00BDT5M118.USD","LU1267930730.SGD","LU0882574139.USD","LU0820561909.HKD","LU1093756168.USD","IE0004445239.USD","LU0672654240.SGD","LU0466842654.USD","LU0354030511.USD","LU1093756325.SGD","LU1023059063.AUD","LU1057294990.SGD","NVO","LU0256863902.USD","IE00BK4W5L77.USD","LU0109391861.USD","LU0354030438.USD","IE00BKVL7J92.USD","IE00BJT1NW94.SGD","LU0114720955.EUR","LU1035775433.USD","BK4532","LU1069344957.HKD","LU0471298694.HKD","LU1064131342.USD","LU0689472784.USD","LU0094547139.USD","IE00B2B36J28.USD","LU0122379950.USD"],"gpt_icon":1},{"id":"2473394064","title":"复方制剂集团起诉 FDA 将礼来的减肥药从短缺名单中删除","url":"https://stock-news.laohu8.com/highlight/detail?id=2473394064","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473394064?lang=zh_cn&edition=full","pubTime":"2024-10-08 05:02","pubTimestamp":1728334964,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透10月7日 - 周一，一家药物合成行业组织起诉美国食品药品管理局，指控该局上周决定将礼来公司的减肥药和糖尿病药从短缺清单中剔除，预计此举将削弱合成企业销售自己生产的药物的能力。在向得克萨斯州沃斯堡联邦法院提起的诉讼中，外包设施协会声称，尽管蒂氮帕肽仍然供不应求，但FDA还是将其从短缺名单中删除了。礼来公司以 Zepbound（减肥药）和 Mounjaro（糖尿病药）两个品牌销售该药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0238689110.USD","LU1069344957.HKD","LU0058720904.USD","LU0354030511.USD","LU0097036916.USD","LU0882574055.USD","LU0256863902.USD","LU0823416689.USD","BK4588","LU0471298777.SGD","IE00B2B36J28.USD","LU0256863811.USD","LU0689472784.USD","LU1093756325.SGD","LU0122379950.USD","LU0106261372.USD","BK4516","LU1035775433.USD","LLY","LU0882574139.USD","LU0385154629.USD","LU0456855351.SGD","IE0002141913.USD","IE00B4R5TH58.HKD","BK4007","LU0820561909.HKD","LU0079474960.USD","IE00BFTCPJ56.SGD","IE00BJLML261.HKD","BK4581","LU1267930730.SGD","LU0354030438.USD","LU0320765059.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","GB00BDT5M118.USD","LU1064131342.USD","LU0466842654.USD","LU0096364046.USD","LU0114720955.EUR","LU0198837287.USD","IE00BJJMRZ35.SGD","LU0471298694.HKD","LU0640476718.USD","LU1061106388.HKD","IE0004445239.USD","LU0820561818.USD","BK4585","LU0943347566.SGD","LU0061475181.USD"],"gpt_icon":0},{"id":"2473910531","title":"礼来涨1.45% 股价突破900美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2473910531","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473910531?lang=zh_cn&edition=full","pubTime":"2024-10-07 21:39","pubTimestamp":1728308364,"startTime":"0","endTime":"0","summary":"北京时间2024年10月07日21时39分，礼来股票出现异动，股价快速拉升1.45%。截至发稿，该股报900.02美元/股，成交量19.2401万股，换手率0.02%，振幅1.12%。最近的财报数据显示，该股实现营业收入113.03亿美元，净利润29.67亿美元，每股收益3.29美元，毛利91.33亿美元，市盈率110.77倍。礼来股票所在的制药行业中，整体涨幅为0.62%。礼来制药公司的主要产品包括治疗癌症的Verzenio;治疗心脏代谢疾病的 Mounjaro、Zepbound、Jardiance、Trulicity、Humalog 和 Humulin；以及治疗免疫学疾病的 Taltz 和 Olumiant。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410072139259719ea21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410072139259719ea21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","LU0354030511.USD","BK4588","LU0106261372.USD","LU0006306889.USD","LU0320765059.SGD","LU0689472784.USD","IE0004445239.USD","IE00B2B36J28.USD","LU1023059063.AUD","LU0385154629.USD","IE0009355771.USD","BK4581","LLY","LU0058720904.USD","LU0096364046.USD","LU1267930730.SGD","LU0354030438.USD","BK4007","LU0943347566.SGD","LU0289739699.SGD","IE00BJT1NW94.SGD","LU0708995401.HKD","LU0094547139.USD","IE0002141913.USD","LU0256863902.USD","LU0097036916.USD","LU0471298777.SGD","LU0820561818.USD","BK4516","LU0198837287.USD","IE00BFTCPJ56.SGD","LU0114720955.EUR","IE00B1BXHZ80.USD","IE00BJLML261.HKD","LU0417517546.SGD","LU0820561909.HKD","LU1035775433.USD","LU0466842654.USD","LU1064131342.USD","LU0456855351.SGD","LU0640476718.USD","LU0122379950.USD","LU1057294990.SGD","LU0882574055.USD","LU0238689110.USD","LU0823416689.USD","LU1069344957.HKD","LU0109391861.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2473172231","title":"新型减肥药(GLP-1)或导致肌肉流失速度快于普通人群 医药巨头警告：可能“弊大于利”","url":"https://stock-news.laohu8.com/highlight/detail?id=2473172231","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473172231?lang=zh_cn&edition=full","pubTime":"2024-10-07 20:21","pubTimestamp":1728303714,"startTime":"0","endTime":"0","summary":"金吾财讯 | 临床数据显示，注射礼来公司 的药物后，其中有25%的体重减轻来自于肌肉等瘦体重的减少，而注射诺和诺德的药物后则有40%的体重减轻是由于瘦体重的下降。据报道，当前，Regeneron公司正在推进研究一种新的药物实验，旨在减少由减肥药物引起的肌肉损失。Yancopoulos同时也担任该司的首席科学官，他表示：“临床研究表明，接受新型减肥药物治疗的患者，其肌肉流失速度远快于通过饮食或运动减肥的人群，这会给他们带来健康问题。”","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"280631","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","LU0289739699.SGD","LU0882574139.USD","LU0689472784.USD","IE00BK4W5M84.HKD","LU0097036916.USD","LU0823416689.USD","IE00BK4W5L77.USD","LU0889565916.HKD","BK4588","IE00BZ1G4Q59.USD","LU1023059063.AUD","BK4007","IE0009355771.USD","LU0096364046.USD","BK4581","GB00BDT5M118.USD","LU2362541513.USD","REGN","LU0198837287.USD","LU0109391861.USD","LU0053666078.USD","09939","IE0004445239.USD","LU0466842654.USD","LU1057294990.SGD","LU0820561909.HKD","LU0354030511.USD","GLP","LU0320765992.SGD","LU2023250504.SGD","LU0882574055.USD","LU0079474960.USD","IE00B1BXHZ80.USD","LU2106854487.HKD","LU0256863902.USD","LLY","LU0154236417.USD","LU0114720955.EUR","BK4534","BK4590","IE00BJJMRZ35.SGD","NVO","LU1917777945.USD","LU1093756325.SGD","BK4533","BK4532","BK1161","LU1069344957.HKD","LU0122379950.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lilly.com","stockEarnings":[{"period":"1week","weight":0.0506},{"period":"1month","weight":0.0121},{"period":"3month","weight":-0.0172},{"period":"6month","weight":0.24},{"period":"1year","weight":0.5267},{"period":"ytd","weight":0.599}],"compareEarnings":[{"period":"1week","weight":0.0115},{"period":"1month","weight":0.0454},{"period":"3month","weight":0.035},{"period":"6month","weight":0.1345},{"period":"1year","weight":0.3365},{"period":"ytd","weight":0.2194}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"礼来公司于1901年在印第安纳州注册成立，其前身是1876年由伊利·礼来上校在印第安纳州印第安纳波利斯创立的药品生产企业。公司发现，开发，制造和销售重要医药产品。公司的宗旨是将“关爱”与“发现”结合起来，为世界各地的人们创造更美好的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.011498},{"month":2,"riseRate":0.5,"avgChangeRate":-0.002909},{"month":3,"riseRate":0.613636,"avgChangeRate":0.015389},{"month":4,"riseRate":0.555556,"avgChangeRate":0.018718},{"month":5,"riseRate":0.422222,"avgChangeRate":0.014916},{"month":6,"riseRate":0.6,"avgChangeRate":0.02296},{"month":7,"riseRate":0.555556,"avgChangeRate":-0.000346},{"month":8,"riseRate":0.422222,"avgChangeRate":0.004313},{"month":9,"riseRate":0.444444,"avgChangeRate":0.001418},{"month":10,"riseRate":0.6,"avgChangeRate":0.015275},{"month":11,"riseRate":0.75,"avgChangeRate":0.027866},{"month":12,"riseRate":0.590909,"avgChangeRate":0.031834}],"exchange":"NYSE","name":"礼来","nameEN":"Eli Lilly"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"礼来,LLY,礼来股票,礼来股票老虎,礼来股票老虎国际,礼来行情,礼来股票行情,礼来股价,礼来股市,礼来股票价格,礼来股票交易,礼来股票购买,礼来股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}